All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Pierre Fenaux, CHU de Nantes, Nantes, FR. We asked, How successful is CPX-351 as first-line treatment for myelodysplastic syndromes (MDS)?
How successful is CPX-351 as first-line treatment for MDS?
In this video, Fenaux discusses CPX-351, a dual-drug liposomal formulation of cytarabine and daunorubicin at a fixed 5:1 molar ratio.
Phase I results of venetoclax combined with azacitidine in high-risk MDS or CMML
During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Alexandre Bazinet1 presented phase I results of the combination of venetoclax and...
What do the PANTHER trial results tell us about first-line treatment for high-risk MDS?
During the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Mikkael Sekeres, Sylvester Comprehensive Cancer Center, Miami, US. We...
Subscribe to get the best content related to MDS delivered to your inbox